PC
MDGL icon

Passport Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

Passport Capital’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,332
Closed -$201K – 223
2014
Q1 		$201K Buy
+1,332
New +$262K 0.01% 157

Other funds holding MDGL

CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Passport Capital's MDGL Position: Q2 2014 in Review

Passport Capital sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2014, closing a stake of 1,332 shares — an estimated $201K sold.

Passport Capital first reported a position in MDGL in Q1 2014 and held it in 1 quarter. The position peaked at $201K in Q1 2014. 82 funds tracked by Wall St. Rank hold MDGL as of Q2 2014.

  • Passport Capital reported no remaining Madrigal Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Passport Capital sold 1,332 Madrigal Pharmaceuticals shares in Q2 2014, an estimated $201K.
  • Passport Capital first reported a position in Madrigal Pharmaceuticals in Q1 2014 and held it in 1 quarter.
  • Passport Capital's Madrigal Pharmaceuticals position peaked at $201K in Q1 2014.
  • 82 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2014.

Based on Passport Capital's 13F filing for Q2 2014, filed 14 Aug 2014.